Following 4 confirmed cases of meningococcal disease and the death of a child between April 21st and May 5th in the Central ...

The valuation, as of 2024, is estimated to be around USD 3950.2 million and is slated to reach USD 9014 million by the end of 2034. Inferring to the ongoing trends, the industry is very likely to ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

Investigations have revealed that four confirmed cases of meningococcal disease are not epidemiologically linked, meaning the ...

Sanofi (SNY) wins FDA label expansion for its MenQuadfi meningococcal vaccine for use in infants as young as six weeks. Read ...

A child has died from meningococcal disease in Fiji. FBC reported the country's Ministry of Health has recorded four ...

Meningococcal vaccines protect against bacterial infections caused by Neisseria meningitidis. These bacteria are capable of causing meningococcal meningitis, a condition that causes inflammation of ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as young as six weeks, expanding its previous label indicated for ...

One of the pediatric patients has died. The Ministry is closely monitoring recent presentations in cases of Meningococcal ...

The approved indication now includes children down to 6 weeks of age to protect against invasive meningococcal disease via serogroups A, C, W, and Y. On May 23, 2025, the FDA approved an expanded ...

The FDA has approved expanded use of Sanofi Pasteur’s Menactra, a meningococcal conjugate vaccine for children aged 2 to 10. Menactra is now the first quadrivalent conjugate vaccine licensed in the U.